Angiogenesis as a Novel Component of Inflammatory Bowel Disease Pathogenesis

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2060-2073

  Danese, Silvio ^a,b   Sans, Miquel ^c,d   de la Motte, Carol ^e   Graziani, Cristina ^b   West, Gail ^c   Phillips, Manijeh H ^c   Pola, Roberto ^a   Rutella, Sergio ^b   Willis, Joe ^c   Gasbarrini, Antonio ^a   Fiocchi, Claudio ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CHORIOALLANTOIS; CONCEPT FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA PERMEABILITY; DRUG ACTIVITY; ENDOTHELIUM; ENDOTHELIUM CELL; ENTERITIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; MEASUREMENT; MICROVASCULATURE; MORPHOMETRICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; UPREGULATION; VASCULARIZATION;

EID: 33744510694     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.03.054     Document Type: Article

References (84)

1. Folkman J., and Shing Y. Angiogenesis. J Biol Chem 267 (1992) 10931-10934
2. Folkman J. Tumor angiogenesis. therapeutic implications. N Engl J Med 285 (1971) 1182-1186
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
5. Gould V.E., and Wagner B.M. Angiogenesis. an expanding universe. Hum Pathol 33 (2002) 1061-1063
6. Majno G. Chronic inflammation. links with angiogenesis and wound healing. Am J Pathol 153 (1998) 1035-1039
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6 (2000) 389-395
8. Bagli E., Xagorari A., Papetropoulos A., Murphy C., and Fotsis T. Angiogenesis in inflammation. Autoimmun Rev 3 Suppl 1 (2004) S26
9. Firestein G.S. Starving the synovium. angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103 (1999) 3-4
10. Szekanecz Z., and Koch A.E. Vascular endothelium and immune responses. implications for inflammation and angiogenesis. Rheum Dis Clin North Am 30 (2004) 97-114
11. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A., and Winkler J.D. The codependence of angiogenesis and chronic inflammation. FASEB J 11 (1997) 457-465
12. Koch A.E. The role of angiogenesis in rheumatoid arthritis. recent developments. Ann Rheum Dis 59 Suppl 1 (2000) i65-i71
13. Creamer D., Sullivan D., Bicknell R., and Barker J. Angiogenesis in psoriasis. Angiogenesis 5 (2002) 231-236
14. Fiocchi C. Inflammatory bowel disease. etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
15. Laroux F.S., and Grisham M.B. Immunological basis of inflammatory bowel disease. role of the microcirculation. Microcirculation 8 (2001) 283-301
16. Hatoum O.A., and Binion D.G. The vasculature and inflammatory bowel disease. contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 11 (2005) 304-313
17. Wakefield A.J., Sawyerr A.M., Dhillon A.P., Pittilo R.M., Rowles P.M., Lewis A.A., and Pounder R.E. Pathogenesis of Crohn's disease. multifocal gastrointestinal infarction. Lancet 2 (1989) 1057-1062
18. Spalinger J., Patriquin H., Miron M.C., Marx G., Herzog D., Dubois J., Dubinsky M., and Seidman E.G. Doppler US in patients with Crohn disease. vessel density in the diseased bowel reflects disease activity. Radiology 217 (2000) 787-791
19. Saito S., Tsuno N.H., Sunami E., Hori N., Kitayama J., Kazama S., Okaji Y., Kawai K., Kanazawa T., Watanabe T., Shibata Y., and Nagawa H. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol 38 (2003) 229-237
20. Fiocchi C., Battisto J.R., and Farmer R.G. Gut mucosal lymphocytes in inflammatory bowel disease. isolation and preliminary functional characterization. Dig Dis Sci 24 (1979) 705-717
21. Binion D.G., West G.A., Ina K., Ziats N.P., Emancipator S.N., and Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 112 (1997) 1895-1907
22. Strong S.A., Pizarro T.T., Klein J.S., Cominelli F., and Fiocchi C. Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. Gastroenterology 114 (1998) 1244-1256
23. Vogel J.D., West G.A., Danese S., de la Motte C., Phillips M.H., Strong S.A., Willis J., and Fiocchi C. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology (2004) 63-80
24. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36 (1995) 169-180
25. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P., Pezzella F., Viale G., Weidner N., Harris A.L., and Dirix L.Y. Quantification of angiogenesis in solid human tumours. an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A (1996) 2474-2484
26. Danese S., de la Motte C., Sturm A., JD V., West G.A., Strong S.A., Katz J., and Fiocchi C. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124 (2003) 1249-1264
27. Vonlaufen A., Wiedle G., Borisch B., Birrer S., Luder P., and Imhof B.A. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 14 (2001) 1126-1132
28. Sturm A., Leite A.Z., Danese S., Krivacic K.A., West G.A., Mohr S., Jacobberger J.W., and Fiocchi C. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 53 (2004) 1624-1631
29. Koch A.E., Volin M.V., Woods J.M., Kunkel S.L., Connors M.A., Harlow L.A., Woodruff D.C., Burdick M.D., and Strieter R.M. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum 44 (2001) 31-40
30. Keane M.P., Arenberg D.A., Lynch III J.P., Whyte R.I., Iannettoni M.D., Burdick M.D., Wilke C.A., Morris S.B., Glass M.C., DiGiovine B., Kunkel S.L., and Strieter R.M. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159 (1997) 1437-1443
31. Danese S., Katz J., Saibeni S., Papa A., Gasbarrini A., Vecchi M., and Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52 (2003) 1435-1441
32. Danese S., de la Motte C., Rivera-Reyes B.M., Sans M., Levine A.D., and Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 172 (2004) 2011-2015
33. Heidemann J., Ogawa H., Dwinell M.B., Rafiee P., Maaser C., Gockel H.R., Otterson M.F., Ota D.M., Lugering N., Domschke W., and Binion D.G. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278 (2003) 8508-8515
34. Pola R., Ling L.E., Silver M., Corbley M.J., Kearney M., Blake Pepinsky R., Shapiro R., Taylor F.R., Baker D.P., Asahara T., and Isner J.M. The morphogen sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 7 (2001) 706-711
35. West D., Thompson W., Sells P., and Burbridge M. Angiogenesis assays using chick chorioallantoic membrane. In: Murray C. (Ed). Angiogenesis protocols. Methods Mol Med (2001) 107-129
36. Eliceiri B.P., and Cheresh D.A. The role of alpha v integrins during angiogenesis. insights into potential mechanisms of action and clinical development. J Clin Invest 103 (1999) 1227-1230
37. Eliceiri B.P., and Cheresh D.A. Role of alpha v integrins during angiogenesis. Cancer J 6 Suppl 3 (2000) S245-S249
38. Gutheil J.C., Campbell T.N., Pierce P.R., Watkins J.D., Huse W.D., Bodkin D.J., and Cheresh D.A. Targeted antiangiogenic therapy for cancer using Vitaxin. a humanized monoclonal antibody to the integrin alpha v beta 3. Clin Cancer Res 6 (2000) 3056-3061
39. Auerbach R., Lewis R., Shinners B., Kubai L., and Akhtar N. Angiogenesis assays. a critical overview. Clin Chem 49 (2003) 32-40
40. Walsh D.A., and Pearson C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 3 (2001) 147-153
41. Hayden M.R., and Tyagi S.C. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. a malignant transformation. Cardiovasc Diabetol 3 (2004) 1
42. McDonald D.M. Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 164 (2001) S39-S45
43. Kanazawa S., Tsunoda T., Onuma E., Majima T., Kagiyama M., and Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis. a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 96 (2001) 822-828
44. McLaren W.J., Anikijenko P., Thomas S.G., Delaney P.M., and King R.G. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 47 (2002) 2424-2433
45. Di Sabatino A., Ciccocioppo R., Armellini E., Morera R., Ricevuti L., Cazzola P., Fulle I., and Corazza G.R. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis 10 (2004) 573-577
46. McDonald D.M., and Choyke P.L. Imaging of angiogenesis. from microscope to clinic. Nat Med 9 (2003) 713-725
47. Romagnani P., Lasagni L., Annunziato F., Serio M., and Romagnani S. CXC chemokines. the regulatory link between inflammation and angiogenesis. Trends Immunol 25 (2004) 201-209
48. Libby P., and Zhao D.X. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation 107 (2003) 1237-1239
49. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
50. Naldini A., and Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 4 (2005) 3-8
51. Max R., Gerritsen R.R., Nooijen P.T., Goodman S.L., Sutter A., Keilholz U., Ruiter D.J., and De Waal R.M. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71 (1997) 320-324
52. Johnson B.A., Haines G.K., Harlow L.A., and Koch A.E. Adhesion molecule expression in human synovial tissue. Arthritis Rheum 36 (1993) 137-146
53. Creamer D., Allen M., Sousa A., Poston R., and Barker J. Altered vascular endothelium integrin expression in psoriasis. Am J Pathol 147 (1995) 1661-1667
54. Varner J.A., and Cheresh D.A. Tumor angiogenesis and the role of vascular cell integrin alphaV beta3. Important Adv Oncol (1996) 69-87
55. Everts M., Scharaa A.J., de Leij L.F., Meijer D.K., and Molema G. Vascular endothelium in inflamed tissue as a target for site selective delivery of drugs. In: Molema G., and Meijer D.K.F. (Eds). Drug targeting (2001), Wiley-VCH, Weinheim 171-197
56. Wilder R.L. Integrin alpha v beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61 Suppl 2 (2002) ii96-ii99
57. Kumar C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4 (2003) 123-131
58. O'Byrne K.J., Dalgleish A.G., Browning M.J., Steward W.P., and Harris A.L. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 36 (2000) 151-169
59. Monaco C., Andreakos E., Kiriakidis S., Feldmann M., and Paleolog E. T-cell-mediated signaling in immune, inflammatory and angiogenic processes. the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 3 (2004) 35-42
60. Jung Y.D., Ahmad S.A., Liu W., Reinmuth N., Parikh A., Stoeltzing O., Fan F., and Ellis L.M. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 12 (2002) 105-112
61. Podolsky D.K., and Fiocchi C. Cytokines, chemokines, growth factors, eicosanoids and other bioactive molecules in IBD. In: Kirsner J.B. (Ed). Inflammatory bowel disease (1999), Saunders, Philadelphia 191-207
62. Beck P.L., and Podolsky D.K. Growth factors in inflammatory bowel disease. Inflam Bowel Dis 5 (1999) 44-60
63. Kunz-Schughart L.A., and Knuechel R. Tumor-associated fibroblasts (part II). functional impact on tumor tissue. Histol Histopathol 17 (2002) 623-637
64. Kunz-Schughart L.A., and Knuechel R. Tumor-associated fibroblasts (part I). active stromal participants in tumor development and progression?. Histol Histopathol 17 (2002) 599-621
65. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2 (2000) 356-360
66. Addison C.L., Arenberg D.A., Morris S.B., Xue Y.Y., Burdick M.D., Mulligan M.S., Iannettoni M.D., and Strieter R.M. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 11 (2000) 247-261
67. Simonini A., Moscucci M., Muller D.W., Bates E.R., Pagani F.D., Burdick M.D., and Strieter R.M. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 101 (2000) 1519-1526
68. Carmeliet P., and Collen D. Molecular analysis of blood vessel formation and disease. Am J Physiol 273 (1997) H2091-H2104
69. Yamashita A., Yonemitsu Y., Okano S., Nakagawa K., Nakashima Y., Irisa T., Iwamoto Y., Nagai Y., Hasegawa M., and Sueishi K. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 168 (2002) 450-457
70. Lee C.G., Link H., Baluk P., Homer R.J., Chapoval S., Bhandari V., Kang M.J., Cohn L., Kim Y.K., McDonald D.M., and Elias J.A. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 10 (2004) 1095-1103
71. Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D., and Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102 (2003) 161-168
72. Khurana R., Zhuang Z., Bhardwaj S., Murakami M., De Muinck E., Yla-Herttuala S., Ferrara N., Martin J.F., Zachary I., and Simons M. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 110 (2004) 2436-2443
73. Ferrante M., Henckaerts L., Hlavaty T., Pierik M., Bueno de Mesquita M., Van Schuerbeek N., Claessens G., Rutgeerts P., Van Assche G., and Vermeire S. Vascular endothelial growth factor (VEGF) polymorphisms are implicated in susceptibility to IBD. Gastroenterology 128 (2005) A441
74. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., and Cheresh D.A. Decreased angiogenesis and arthritic disease in rabbits treated with an alpha v beta 3 antagonist. J Clin Invest 103 (1999) 47-54
75. Wilson J.F. Angiogenesis therapy moves beyond cancer. Ann Intern Med 141 (2004) 165-168
76. Canete J.D., Pablos J.L., Sanmarti R., Mallofre C., Marsal S., Maymo J., Gratacos J., Mezquita J., Mezquita C., and Cid M.C. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 50 (2004) 1636-1641
77. Moulton K.S., Vakili K., Zurakowski D., Soliman M., Butterfield C., Sylvin E., Lo K.M., Gillies S., Javaherian K., and Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100 (2003) 4736-4741
78. Bian X.W., Chen J.H., Jiang X.F., Bai J.S., Wang Q.L., and Zhang X. Angiogenesis as an immunopharmacologic target in inflammation and cancer. Int Immunopharmacol 4 (2004) 1537-1547
79. Ballara S.C., Miotla J.M., and Paleolog E.M. New vessels, new approaches. angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol 80 (1999) 235-250
80. Griffioen A.W., and Molema G. Angiogenesis. potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52 (2000) 237-268
81. Schraa A.J., Everts M., Kok R.J., Asgeirsdottir S.A., Meijer D.K., de Leij L.F., and Molema G. Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. Biotechnol Annu Rev 8 (2002) 133-165
82. Danese S., Sans M., Spencer D.M., Beck I., Fernando D., Plunkett M., Campbell M., West G.A., Redline R., Gasbarrini A., Mazar A., de La Motte C., Levine A.D., and Fiocchi C. Starving the inflamed gut. angiogenesis blockade as a novel therapeutic approach to experimental colitis. Gastroenterology 128 (2005) A40
83. Goedkoop A.Y., Kraan M.C., Picavet D.I., de Rie M.A., Teunissen M.B., Bos J.D., and Tak P.P. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. a prospective single-centre study. Arthritis Res Ther 6 (2004) R326-R334
84. Dredge K., Dalgleish A.G., and Marriott J.B. Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs 4 (2003) 667-674